Metabolic Dysfunction in Non-alcoholic Fatty Liver Disease: From Bench to Bedside

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Nutrition and Metabolism".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 2736

Special Issue Editors

Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK
Interests: NAFLD; microbiome and intestinal permeability; screening for liver disease
Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK
Interests: NAFLD; microbiome and intestinal permeability; NAFLD and obesity

Special Issue Information

Dear Colleague,

Non-alcoholic fatty liver disease is now a leading cause of liver disease and hepatocarcinoma (HCC) worldwide. NAFLD has also become the fastest-growing cause of liver transplantation. We have now moved from an old concept of NAFLD being a dichotomic disease to a more dynamic disease model explained by a multi-hit hypothesis. Overall, a plethora of dietary, environmental, and genetic factors may contribute to the disease and determine the worsening of metabolic status and insulin resistance. Nevertheless, identifying the factors associated with more severe liver disease and worse outcomes remains challenging in this group of patients.

The aim of this Special Issue is to include the latest evidence on factors impacting the metabolic status and the severity of liver disease/clinical outcomes in patients with NAFLD. The portfolio of this issue will range from molecular pathways to translational research. 

Dr. Roberta Forlano
Dr. Giordano Sigon
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • NAFLD
  • NASH
  • HCC
  • fibrosis
  • screening
  • risk stratification
  • cardiovascular disease
  • metabolites
  • microbiome
  • gut–liver axis

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 1491 KiB  
Review
Screening for NAFLD—Current Knowledge and Challenges
by Roberta Forlano, Giordano Sigon, Benjamin H. Mullish, Michael Yee and Pinelopi Manousou
Metabolites 2023, 13(4), 536; https://doi.org/10.3390/metabo13040536 - 09 Apr 2023
Cited by 5 | Viewed by 2428
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver function tests worldwide, with an estimated prevalence ranging between 19–46% in the general population. Of note, NAFLD is also expected to become a leading cause of end-stage liver disease in [...] Read more.
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver function tests worldwide, with an estimated prevalence ranging between 19–46% in the general population. Of note, NAFLD is also expected to become a leading cause of end-stage liver disease in the next decades. Given the high prevalence and severity of NAFLD, especially in high-risk populations (i.e., patients with type-2 diabetes mellitus and/or obesity), there is a major interest in early detection of the disease in primary care. Nevertheless, substantial uncertainties still surround the development of a screening policy for NAFLD, such as limitations in currently used non-invasive markers of fibrosis, cost-effectiveness and the absence of a licensed treatment. In this review, we summarise current knowledge and try to identify the limitations surrounding the screening policy for NAFLD in primary care. Full article
Show Figures

Figure 1

Back to TopTop